Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Nektar Therapeutics (NKTR)

0.7029   0.067 (10.52%) 03-31 16:00
Open: 0.6561 Pre. Close: 0.636
High: 0.7067 Low: 0.62
Volume: 16,103,211 Market Cap: 133(M)

Technical analysis

as of: 2023-03-31 4:20:47 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 1.42     One year: 1.86
Support: Support1: 0.6    Support2: 0.5
Resistance: Resistance1: 1.21    Resistance2: 1.6
Pivot: 0.88
Moving Average: MA(5): 0.7     MA(20): 0.98
MA(100): 2.39     MA(250): 3.32
MACD: MACD(12,26): -0.4     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 7.8     %D(3): 4.9
RSI: RSI(14): 24.6
52-week: High: 6.26  Low: 0.6
Average Vol(K): 3-Month: 3,136 (K)  10-Days: 7,379 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ NKTR ] has closed above bottom band by 26.6%. Bollinger Bands are 28.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.71 - 0.71 0.71 - 0.71
Low: 0.61 - 0.62 0.62 - 0.62
Close: 0.7 - 0.7 0.7 - 0.71

Company Description

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

Headline News

Thu, 30 Mar 2023
Why Is Nektar (NKTR) Down 51.9% Since Last Earnings Report? - Nasdaq

Wed, 29 Mar 2023
Nektar Therapeutics slips, PacWest Bancorp gains on S&P index ... - Seeking Alpha

Fri, 24 Mar 2023
Nektar (NKTR) Upgraded to Buy: Here's Why - Nasdaq

Tue, 21 Mar 2023
Nektar Therapeutics (NASDAQ:NKTR) Given Consensus ... - MarketBeat

Tue, 14 Mar 2023
Sage Therapeutics, Inc. (SAGE) Soars 9.6%: Is Further Upside Left ... - Nasdaq

Mon, 13 Mar 2023
Nektar Therapeutics Has No Exposure to Silicon Valley Bank By ... - India

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 188 (M)
Shares Float 186 (M)
% Held by Insiders 1.3 (%)
% Held by Institutions 89.4 (%)
Shares Short 9,930 (K)
Shares Short P.Month 9,000 (K)

Stock Financials

EPS -2.5
EPS Est Next Qtl -0.35
EPS Est This Year -0.99
EPS Est Next Year -1.11
Book Value (p.s.) 5.98
Profit Margin (%) 0
Operating Margin (%) -328.6
Return on Assets (ttm) -19
Return on Equity (ttm) -74.9
Qtrly Rev. Growth -5.2
Gross Profit (p.s.) 0.4
Sales Per Share 0.5
EBITDA (p.s.) -1.6
Qtrly Earnings Growth 0
Operating Cash Flow -398 (M)
Levered Free Cash Flow -189 (M)

Stock Valuations

PE Ratio -0.29
PEG Ratio 0.1
Price to Book value 0.11
Price to Sales 1.39
Price to Cash Flow -0.34

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.